Actemra (Tocilizumab)

Actemra is a medicine for rheumatoid arthritis, giant cell arteritis and some kinds of juvenile arthritis, and it is also used in hospitals for severe immune reactions. It is given as a shot under the skin or as an IV infusion. It works by blocking IL-6, a signal that drives inflammation in the body.

Brand names:Actemra, Tyenne, Tofidence, Avtozma
Medication

What people taking Actemra (Tocilizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Actemra (Tocilizumab) for Giant Cell Arteritis?

NameHow it went

About Actemra (Tocilizumab)

What It's For

Tocilizumab, sold as Actemra, is a prescription biologic medicine that calms an overactive immune system. Its main long-term use is for adults with moderate to severe rheumatoid arthritis whose joints remain inflamed after at least one standard disease-modifying antirheumatic drug (DMARD), such as methotrexate. It is also approved for giant cell arteritis, an inflammation of the body's large arteries, and for two forms of childhood arthritis (polyarticular and systemic juvenile idiopathic arthritis) in children 2 and older. In adults with systemic sclerosis (scleroderma) that has affected the lungs, Actemra is approved to slow the loss of lung function. In hospitals, intravenous tocilizumab has two short-term uses: treating severe cytokine release syndrome, a dangerous surge of inflammation that can follow CAR T cell therapy for blood cancers, and treating people hospitalized with COVID-19 who are already on steroids and need oxygen or breathing support. Three biosimilars, Tyenne, Tofidence and Avtozma, are FDA-approved versions shown to be highly similar to Actemra. Their approved uses overlap with Actemra's but are not identical (none is labeled for the scleroderma lung indication, and Tofidence comes only as an infusion), so the specific product matters.

How It Works

Interleukin-6 (IL-6) is a signaling protein that immune cells release to drive inflammation. In rheumatoid arthritis it is produced inside inflamed joints, and throughout the body it tells the liver to make inflammation proteins such as C-reactive protein (CRP). Tocilizumab is a laboratory-made antibody that attaches to the receptor IL-6 must bind to, so the signal cannot get through. With less IL-6 activity, joint swelling, artery inflammation, fever and the inflammatory blood markers tend to fall. The same effect has a practical downside: because IL-6 also helps the body mount fever and other early signs of infection, an infection can look milder than it really is while someone is taking tocilizumab.

Dosage & Administration

Tocilizumab comes in two forms. The intravenous (IV) form is given in a clinic or hospital as a one-hour infusion, with the dose based on body weight, usually every four weeks for adult arthritis and giant cell arteritis. The subcutaneous form is a 162 mg injection under the skin from a prefilled syringe or the ACTPen autoinjector, typically every week or every other week depending on the condition, weight and response. Children's schedules are set by weight. For giant cell arteritis, tocilizumab is started alongside a steroid such as prednisone that is gradually tapered, and it can continue alone once steroids stop. Before the first dose, the care team checks for tuberculosis (TB) with a skin or blood test, because tocilizumab can let a hidden TB infection become active; latent TB is treated first. Baseline blood counts and liver tests are also checked. The first subcutaneous injection is given under a clinician's supervision, after which many people inject at home. Injections are taken out of the refrigerator to reach room temperature before use, and if a full dose was not received, the prescriber should be told.

Side Effects

The most common side effects are colds and other upper respiratory infections, headache, higher blood pressure, raised liver enzymes on blood tests, and redness or irritation where the injection was given. Blood tests may also show lower white blood cell or platelet counts and higher cholesterol, usually without symptoms, which is why regular testing matters. Tocilizumab carries the FDA's strongest (boxed) warning for serious infections, including pneumonia, shingles, TB and fungal infections, which can lead to hospitalization or death. The risk is higher in people also taking methotrexate or steroids. Contact the care team right away for fever, chills, a persistent cough, painful skin or other signs of infection, even if they seem mild; treatment is paused until a serious infection is controlled. Two less common problems need prompt attention. Fever with severe, persistent belly pain or a change in bowel habits can signal a tear in the intestine, mostly in people with diverticulitis. Yellowing of the skin or eyes, dark urine, pain in the upper right abdomen, unusual tiredness or loss of appetite can signal liver injury, which has been serious in rare cases and can appear months or years into treatment. Call the care team promptly for either. Serious allergic reactions, including anaphylaxis, can occur, even with the first dose. Get emergency care for hives with swelling of the face, lips, tongue or throat, or trouble breathing or swallowing.

Interactions & Warnings

Tocilizumab is not combined with other biologic immune-suppressing drugs, such as tumor necrosis factor (TNF) blockers like adalimumab (Humira), because the added suppression raises infection risk. It is commonly used with methotrexate or other non-biologic DMARDs. Inflammation slows the liver enzymes that break down many drugs. By reducing inflammation, tocilizumab can speed them back up and lower the levels of certain medicines. This matters most for drugs whose dose is finely adjusted, such as the blood thinner warfarin, the transplant drug cyclosporine and the asthma drug theophylline, and for medicines where reduced effect is a problem, such as hormonal birth control and some statins (cholesterol drugs). The effect can last several weeks after stopping, so these medicines may need extra monitoring when tocilizumab is started or stopped. Live vaccines (vaccines made from weakened live germs) should be avoided during treatment, and it helps to catch up on vaccinations before starting. Tocilizumab is generally not recommended for people with active liver disease, and people with diverticulitis, a history of serious or recurrent infections, past TB exposure, or multiple sclerosis or similar nerve conditions need extra discussion. There is not enough human data to know whether tocilizumab harms a pregnancy, and animal studies suggest possible risk. The antibody crosses the placenta late in pregnancy, which affects the timing of live vaccines for the newborn. Anyone pregnant or planning pregnancy should discuss it with their prescriber, as should anyone breastfeeding.

What to Expect

In rheumatoid arthritis, the goal is less joint pain, stiffness and swelling, and the clinical trials judged response after about six months. If the response is incomplete, the dose or injection frequency may be increased, or a different treatment considered. In giant cell arteritis, a main goal is to keep the disease controlled while the steroid dose comes down. Regular blood tests are part of treatment: white blood cells, platelets and liver enzymes are typically checked a month or two after starting and every few months afterward, with cholesterol checked early on. Results can lead to a lower dose, a longer gap between doses or a pause. Because tocilizumab lowers CRP and can blunt fever, these usual clues to infection or disease activity are less reliable, so new symptoms are worth reporting rather than waiting for a test to explain them. For arthritis and giant cell arteritis, tocilizumab is usually an ongoing treatment, and any pause, such as during a serious infection, is planned with the prescriber. In the hospital uses, it is a short course given during the illness rather than ongoing therapy.

Questions to Ask Your Doctor

  1. 1.Why is tocilizumab a better fit for me than another biologic or a pill-based treatment, and which product (Actemra or a biosimilar) will I receive?
  2. 2.Should I have infusions or self-injections, and how often?
  3. 3.Which blood tests will I need, how often, and what results would change my dose?
  4. 4.Which of my current medicines, including birth control or blood thinners, need adjusting, and which vaccines should I get before starting?
  5. 5.What should I do if I get a fever or infection, or if I need surgery, while on treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.